FDMT

4D Molecular Therapeutics, Inc. Common Stock

8.97

USD

FDMT Earnings Reports

Positive Surprise Ratio

FDMT beat 13 of 20 last estimates.

65%

Next Report

Date of Next Report

Feb 27, 2026

Estimate for Q4 25 (Revenue/ EPS)

$9.36M

-$0.77

Implied change from Q3 25 (Revenue/ EPS)

+10304.00%

-23.76%

Implied change from Q4 24 (Revenue/ EPS)

+936260.00%

-14.44%

4D Molecular Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 10, 2025, FDMT reported earnings of -1.01 USD per share (EPS) for Q3 25, missing the estimate of -0.99 USD, resulting in a -1.18% surprise. Revenue reached 90.00 thousand, compared to an expected 293.62 thousand, with a -69.35% difference. The market reacted with a -3.14% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 12 analysts forecast an EPS of -0.77 USD, with revenue projected to reach 9.36 million USD, implying an decrease of -23.76% EPS, and increase of 10304.00% in Revenue from the last quarter.

FAQ

What were 4D Molecular Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, 4D Molecular Therapeutics, Inc. Common Stock reported EPS of -$1.01, missing estimates by -1.18%, and revenue of $90.00K, -69.35% below expectations.

How did the market react to 4D Molecular Therapeutics, Inc. Common Stock's Q3 2025 earnings?

The stock price moved down -3.14%, changed from $10.50 before the earnings release to $10.17 the day after.

When is 4D Molecular Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Feb 27, 2026.

What are the forecasts for 4D Molecular Therapeutics, Inc. Common Stock's next earnings report?

Based on 12 analysts, 4D Molecular Therapeutics, Inc. Common Stock is expected to report EPS of -$0.77 and revenue of $9.36M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.